Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stroke treatment firm reels in €3m

This article was originally published in Clinica

Executive Summary

Electrical Brain Synchronisation (EBS) Technologies, a German start-up specialising in treatment of neurological deficits in stroke and brain trauma patients, has raised €3m ($4.3m) in its second financing round. Earlybird Venture Capital was the lead investor; BC Brandenburg Capital and High-Tech Gründerfonds also participated in the financing. EBS is developing a therapy that provides noninvasive electrical stimulation to the brain, using head-mounted electrodes. The therapy aims to help the brain "re-learn" its natural synchronisation, particularly for vision and speech functions, and facilitate better and faster rehabilitation. The €3m raised will enable the Kleinmachnow-based firm to take its medical device to market and carry out further clinical for additional indications.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT045245

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel